While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...

The Recommended Uniform Screening Panel now includes DMD and MLD, which has implications for firms developing treatments for ...

The firm's Phase I/II study yielded responses in mCRPC patients with androgen receptor mutations but it wasn't as promising in HR-positive breast cancer.

The FDA converted the PARP inhibitor's 2020 accelerated approval to full approved based on results from the Phase III TRITON3 trial.

The grant will fund preclinical studies of the dCK inhibitor TRE-515 with KRAS inhibitors in mice, which will then inform the design of clinical trials.

Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over two years old.

The UC Berkeley spin-out aims to develop one-time treatments for chronic and rare diseases using an RNA- and LNP-based platform.

Experts at SABCS said better prospective trials of ctDNA and more sensitive assays could bring ctDNA testing in breast cancer ...

The firm will share updated data and new analyses from its Phase III trial with the agency, which issued a complete response ...

The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

The firm expects to begin the Phase I trial in HER2-positive breast and gastric cancers in the first half of 2026.